

## Biophytis Announces Launch of a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders

Paris, (France), Cambridge (Massachusetts, United States), April 7, 2020, 8:00 a.m. CEST - Biophytis SA (Euronext Growth Paris: ALBPS a clinical-stage biotechnology company specialized in the development of drug candidates for treatment of aged related diseases, amongst which neuromuscular diseases, today announces the launch of a public offering, of 7,445,123 Share Subscription Warrants (BSA), at a unit price of €0.06 by way of a public offering with an irreducible priority subscription period for existing shareholders. The offer could be increased to 7,475,708 BSA pursuant to an extension clause.

### BSA Offering

The proposed issuance of the 7,445,123 BSA, to be subscribed in cash, will be carried out with shareholders preferential right of subscription removed. The Offer will include (i) a priority period for shareholders on an irreducible basis only, with 3 BSA for 16 shares as of April 8, 2020 (rounded to the higher unit if the number of shares is not a multiple of 16) and (ii) an extension clause to increase the issue to 7,475,708 BSA.

The subscription price will be 0.06 euro per BSA.

Shareholders registered as of April 8, 2020 will benefit from a non-negotiable and non-transferable subscription priority period, from April 9, 2020 to April 21, 2020 included at 12:00 p.m. (Paris time).

As part of the priority period, the Company's shareholders will be able to subscribe on an irreducible basis to the extent of their shares in the Company's capital pursuant to the parity here above. There are no plans to subscribe on a reducible basis as part of the priority period.

Unsubscribed BSAs will then be offered as a priority to the Company's employees and executive officers within the limits of their requests. The Priority Period relates to the initial issuance amount, excluding the extension clause.

The BSAs that remain unsubscribed following the above mentioned priorities including the Company's shareholders, employees and executive officers, will be part of a public offering (including the Company's shareholders in case of additional requests) open in France from April 9, 2020 to April 21, 2020 included, at 12pm (Paris time).

The extension clause will allow the subscription of a maximum of 30,585 additional BSA at the offer price.

The settlement-delivery of the BSA issue is scheduled for April 30, 2020. Newly issued BSAs will bear rights from that date.

BSA will trade on Euronext Growth under the code ISIN FR0013507290. BSA admission to Euronext Growth trading will take place on 5 May 2020.

The BSA can be exercised for a period of 5 years from the date of settlement-delivery, at an exercise price of €0.27 per new share. Each BSA will give its holder the right to subscribe to one (1) new Biophytis share.

The new shares resulting from exercise of the BSA will be ordinary shares equivalent to the Company's existing shares. They will become immediately effective and grant holders, upon delivery, all the rights attached to the shares, and will be subject to periodic requests for trading admission on Euronext Growth, under the same listing as the existing shares.

The net proceeds from the issuance of BSA and the resulting capital increase will be used by the Company to strengthen its financial resources, contributing particularly to funding (i) the finalization of the Phase 2b study for Sarconeos (BIO101) in Sarcopenia, in view to obtain proof of concept clinical data, regarding the product's efficacy, safety and tolerance in severely affected patients, (ii) the launch of the MYODA clinical study in Duchenne myopathy and (iii) the implementation of the new COVA clinical development program. The proceeds will complement the financing tools already in place and will allow the Company to fund its operations beyond the next 12 months.

This public offering is described in a Synthetic Information Document (DIS) posted on the websites of the AMF and Biophytis.

## **About BIOPHYTIS**

Biophytis SA is a clinical-stage biotechnology company specialized in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, especially neuromuscular diseases.

Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in the United States and Europe. A pediatric formulation of BIO101 is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company plans to start the clinical development in H2 2020.

Sarconeos (BIO101) will also be developed as a treatment for Covid-19 (Coronavirus) for which the company has filed a clinical trial application with the French Regulatory Authority (ANSM).

The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information [www.biophytis.com](http://www.biophytis.com).

**Disclaimer**

This press release contains forward-looking statements. While the Company considers its projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements. For a description of the risks and uncertainties likely to affect the results, BIOPHYTIS' financial position, performance or achievements and thus cause a change from the forward-looking statements, please refer to the "Risk Factors" section of the Company's 2018 Annual Report available on BIOPHYTIS website ([www.biophytis.com](http://www.biophytis.com)).

This press release, and the information contained in it, does not constitute an offer to sell or subscribe, nor the solicitation of a purchase or subscription order, of BIOPHYTIS shares in any country. The elements contained in this communication may contain forward-looking information involving risks and uncertainties. The Company's actual achievements may differ materially from those anticipated in this information due to different risk and uncertainty factors. This press release was written in French and English; If there is a difference between the texts, the French version will prevail.

**Biophytis Contact for Investor Relations**

Evelyne Nguyen, CFO

[evelyne.nguyen@biophytis.com](mailto:evelyne.nguyen@biophytis.com)

**Media contact*****Citigate Dewe Rogerson***

Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussart

[biophytis@citigatedewerogerson.com](mailto:biophytis@citigatedewerogerson.com)

Tel: +44 (0) 20 7638 9571 / +33 (0)6 59 42 29 35